Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

basilea pharmaceutica deutschland gmbh - ceftobiprolmedocaril - pulver til koncentrat til infusionsvæske, opløsning - 500 mg

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - meropenem (trihydrat) - pulver til injektions-/infusionsvæske, opløsning - 500 mg

Європейський Союз - данська - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Європейський Союз - данська - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

octapharma ab - normalt immunglobulin, humant - injektionsvæske, opløsning - 165 mg/ml

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

octapharma ab - anti-d immunglobulin, humant - injektionsvæske, opløsning - 625 ie/ml

Європейський Союз - данська - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane sulfat, natrium tazobactam - bakterieinfektioner - antibakterielle midler til systemisk brug, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

biotest pharma gmbh - hepatitis b immunglobulin, humant, plasmaprotein, humant - infusionsvæske, opløsning - 50 ie/ml

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

aspen pharma trading limited - chlorambucil - filmovertrukne tabletter - 2 mg

Данія - данська - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - chlorambucil - filmovertrukne tabletter - 2 mg